Epigral Q4 FY26 Earnings Preview Expectations Outlook

Updated: 20 Mar 2026 • 12:45 pm

Posted by:

Epigral Q4 FY26 Earnings Preview Expectations Outlook

Epigral Q4 FY26 results date is all set to be announced soon and most investors are awaiting it. Professionals are expecting an increase in revenue due to higher sales and a significant rise in PAT. Epigral Limited was listed on the National Stock Exchange (NSE) on 21-Jul-2021. Epigral share has its face value of 10 per share, and its NSE symbol is EPIGRAL. The company operates in the Chemicals sector and primarily belongs to the Specialty Chemicals industry.

Table of Contents

Epigral Q4 Results 2026 Preview

Epigral Q4 FY26 revenue is expected to be around High Growth, representing a 14% YoY increase compared to the same quarter last year.
Profit After Tax, or PAT, is projected to rise 15% YoY.
EBITDA to rise 14%.
Epigral is expected to show High Growth in its revenue.

Click and Sign Up to Get Live Updates on Q4 Results

Epigral Share Performance

Over the past six months, Epigral share price has Positive by 13% to 859.4.
Moreover, over the past year, the stock has Positive by 19%
Despite this weak short-term performance, Epigral stock has delivered a financially sound 130% return over the past 5 years.
As of today, 18-03-2026, the Epigral share price is trading at 859.4 per share.

Key Factors to Watch for Epigral Q4 Results FY26

Revenue Growth & Segment Performance – Focus on topline growth in the Specialty Chemicals industry within the Chemicals sector.
Occupancy Levels & Seat Expansion – Monitor operational expansion and capacity utilisation trends.
Profitability & Margin Trends – Track EBITDA and PAT margins to evaluate cost control and operating efficiency.
Order Book & New Client Wins – Watch for updates on new contracts, partnerships, and long-term deals.
Balance Sheet & Cash Flow Position – Review debt levels, working capital management, and operating cash flows for financial stability.

About Epigral

Epigral manufactures specialty chemicals including derivatives of chlor alkali.

Download the Univest iOS App or Univest Android App to get daily stock recommendations and insightful research pieces!

Final Thoughts

Epigral is gear up to announce its Q4 FY26 results. Analysts expect 14% revenue growth, a 15% rise in PAT, and a 14% rise in EBITDA. Epigral focuses on revenue growth from order execution, margin improvement, a strong order book, and management.

Stay informed with Univest blogs to get real-time updates on Epigral Q4 results FY26.

Disclaimer: Investment in the share market is subject to risk. This news article is for informational purposes only. Conduct your own research before investing in shares and other securities.